YTHDF1 and neoplasm: On the delivery front, immune-cell-targeted nanoparticles (e.g., TAM/DC-directed carriers for YTHDF1 siRNA) and tumor-tropic ligands enable compartment-specific epitranscriptome editing while sparing non-target tissues—critical given widespread physiologic roles of RNA-modification enzymes (153).